NEW ORLEANS, LA–(Marketwired – Aug 04, 2017) – Kahn Swick Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until Sep 29, 2017 to record lead plaintiff applications in a bonds category movement lawsuit opposite IntelliPharmaCeutics International, Inc. (NASDAQ: IPCI), if they purchased a Company’s shares between Jan 14, 2016 and Jul 26, 2017, thorough (the “Class Period”). This movement is tentative in a United States District Court for a Southern District of New York.
What You May Do
If we purchased shares of IntelliPharmaCeutics and would like to plead your authorised rights and how this box competence impact we and your right to redeem for your mercantile loss, we may, though requirement or cost to you, hit KSF Managing Partner Lewis Kahn toll-free during 1-877-515-1850 or around email ( rel=”nofollow”firstname.lastname@example.org), or revisit http://ksfcounsel.com/cases/nasdaqcm-ipci/ to learn more. If we wish to offer as a lead plaintiff in this category action, we contingency petition a Court by September 29, 2017.
About a Lawsuit
IntelliPharmaCeutics and certain of a executives are charged with unwell to divulge element information during a Class Period, violating sovereign bonds laws.
The purported fake and dubious statements and omissions include, though are not singular to, that: (i) a Company unsuccessful to perform tellurian abuse contrast to support a New Drug Application (“NDA”) for Rexista; (ii) a Company unsuccessful to embody studies conducted to support Rexista’s tag claims per tellurian abuse by several pathways; (iii) a Company was not submitting information to amply support capitulation of a NDA; and (iv) as a outcome of a foregoing, IntelliPharmaCeutics’ financial statements were materially fake and dubious during all applicable times.
About Kahn Swick Foti, LLC
KSF, whose partners embody former Louisiana Attorney General Charles C. Foti, Jr., is a law organisation focused on securities, antitrust and consumer category actions, along with partnership merger and crack of fiduciary lawsuit opposite publicly traded companies on interest of shareholders. The organisation has offices in New York, California and Louisiana.
To learn some-more about KSF, we might revisit www.ksfcounsel.com.